ImmunityBio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: ALT-803Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabBiological: bevacizumabProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387098
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Phase 2
Recruiting
- Conditions
- Merkel Cell CarcinomaCervical CancerMismatch Repair DeficiencyMelanomaColorectal CancerUrothelial CarcinomaGastric CancerMicrosatellite InstabilityNon-Small Cell Lung CancerSmall Cell Lung Cancer
- Interventions
- Drug: N-803 + NivolumabDrug: N-803 + Nivolumab + PD-L1 t-haNKDrug: N-803 + Docetaxel + Nivolumab
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03228667
- Locations
- 🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Urothelial Carcinoma
- Interventions
- Drug: 5Fluorouracil (5-FU)Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Phase 1
Withdrawn
- Conditions
- Ovarian Cancer
- Interventions
- Radiation: Stereotactic Body Radiation TherapyBiological: haNK®
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197584
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1
Withdrawn
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169790
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738